{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:13:15Z","timestamp":1785143595043,"version":"3.55.0"},"reference-count":30,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematol. Rep.","Hematology Reports"],"abstract":"<jats:p>Background\/Objectives: CAR T-cell therapy is a highly efficacious therapy option for relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL), but its widespread use is currently limited by safety concerns and high healthcare costs. Methods: We evaluated 66 patients with R\/R LBCL treated with tisagenlecleucel or axicabtagene ciloleucel between 2016 and 2022 at a single institution to identify factors associated with increased healthcare utilization. Results: The median age of our cohort was 59.5 years, with 22.7% over the age of 70. The median length of stay (LOS) during the initial hospitalization was 12 days (range, 7\u201362 days). Longer initial hospital LOS was linked to higher age-adjusted HCT-CI score (IRR 1.08; 95% CI, 1.01 to 1.15; p = 0.0203), thrombocytopenia grade 3\u20134 (IRR 1.32; 95% CI, 1.07 to 1.63; p = 0.0091), and first ICU admission (IRR 1.81; 95% CI, 1.37 to 2.38; p &lt; 0.00001). Thirty- and 90-day readmission rates post-discharge after receiving CAR T-cell therapy were 21.2% and 28.8%, respectively. Multiple readmissions within 90 days after initial hospital discharge were observed in 15% of patients. Longer 30-day readmission LOS was linked to initial hospital LOS (IRR 1.23; 95% CI, 1.11 to 1.35; p &lt; 0.0001) but outpatient follow-up was associated with shorter 30-day readmission LOS (IRR 0.43; 95% CI, 0.26\u20130.69; p = 0.0005). Factors associated with longer 90-day readmission LOS included a greater number of ER visits within 60 days of CAR T-cell therapy (IRR 3.10; 95% CI, 2.15\u20134.46), prior 30-day readmission LOS (IRR 1.35; 95% CI, 1.14\u20131.60), and SUVmax at Day 30 (IRR 1.06; 95% CI, 1.03\u20131.09) (all p-values &lt; 0.0001). Conclusions: Our findings identify key clinical and utilization variables associated with initial and repeat hospitalizations post-CAR T-cell therapy, emphasizing the need for targeted interventions to reduce readmissions and optimize post-discharge care.<\/jats:p>","DOI":"10.3390\/hematolrep18040052","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:15:56Z","timestamp":1785140156000},"page":"52","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors Associated with Increased Healthcare Utilization Within 30 and 90 Days Post-Discharge of CAR-T Cell Therapy in Patients with R\/R LBCL"],"prefix":"10.3390","volume":"18","author":[{"given":"Philip","family":"Yeung","sequence":"first","affiliation":[{"name":"Master of Advanced Studies (MAS) Program in Clinical Research, University of California San Diego, La Jolla, CA 92093, USA"},{"name":"KUMC Master of Science Health Data Science Program, University of Kansas Medical Center, Kansas City, KS 66160, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Trando","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2752-1554","authenticated-orcid":false,"given":"Ah-Reum","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Blood and Marrow Transplantation, University of California San Diego, La Jolla, CA 92093, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4515-4428","authenticated-orcid":false,"given":"Dimitrios","family":"Tzachanis","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Scripps Cancer Center, La Jolla, CA 92037, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3892\/mmr.2024.13171","article-title":"CAR-T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)","volume":"29","author":"Sun","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.2023023419","article-title":"CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: A meta-analysis","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"key":"ref_6","first-page":"CD013365","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma","volume":"9","author":"Ernst","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13613-024-01247-9","article-title":"Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: A French multicentre cohort","volume":"14","author":"Couturier","year":"2024","journal-title":"Ann. Intensiv. Care"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1001\/jamaoncol.2022.1044","article-title":"Assessment of Hospitalizations and Emergency Department Visits After Chimeric Antigen Receptor T-Cell Therapy Among Commercially Insured Patients","volume":"8","author":"Kenzik","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"108.e1","DOI":"10.1016\/j.jtct.2022.11.004","article-title":"Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients","volume":"29","author":"Sharma","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e397912","DOI":"10.1200\/EDBK_397912","article-title":"High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"pkae059","DOI":"10.1093\/jncics\/pkae059","article-title":"Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas","volume":"8","author":"Di","year":"2024","journal-title":"JNCI Cancer Spectr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1007\/s12325-024-02917-7","article-title":"Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma","volume":"41","author":"Wu","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jtct.2024.02.019","article-title":"Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell Therapy","volume":"30","author":"Johnson","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"928","DOI":"10.6004\/jnccn.2020.7678","article-title":"Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy","volume":"19","author":"Johnson","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/cc1820","article-title":"Statistics review 6: Nonparametric methods","volume":"6","author":"Whitley","year":"2002","journal-title":"Crit. Care"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Etzioni, R.B., Mandel, M., and Gulati, R. (2020). Statistics for Health Data Science: An Organic Approach, Springer. [1st ed.]. Springer texts in statistics.","DOI":"10.1007\/978-3-030-59889-1"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Fernandez, G.A., and Vatcheva, K.P. (2022). A comparison of statistical methods for modeling count data with an application to hospital length of stay. BMC Med. Res. Methodol., 22.","DOI":"10.1186\/s12874-022-01685-8"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Harrell, F.E. (2015). Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis, Springer International Publishing. [2nd ed.].","DOI":"10.1007\/978-3-319-19425-7"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Trando, A., Ter-Zakarian, A., Yeung, P., Goodman, A.M., Hamdan, A., Hurley, M., Jeong, A.-R., and Tzachanis, D. (2023). Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience. Cancers, 15.","DOI":"10.3390\/cancers15184671"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1002\/cam4.4797","article-title":"Demographic differences among patients treated with chimeric antigen receptor T-cell therapy in the United States","volume":"11","author":"Emole","year":"2022","journal-title":"Cancer Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e70831","DOI":"10.1002\/cam4.70831","article-title":"Sex Differences in Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy","volume":"14","author":"Tan","year":"2025","journal-title":"Cancer Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1080\/10428194.2022.2060503","article-title":"Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: An analysis of hospital data in the United States","volume":"63","author":"Maziarz","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Tix","year":"2024","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/bloodadvances.2021006715","article-title":"Day 30 SUVmax predicts progression in patients with lymphoma achieving PR\/SD after CAR T-cell therapy","volume":"6","author":"Feng","year":"2022","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.clml.2023.06.005","article-title":"Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma with a Day 28 Partial Response by 18F-FDG PET\/CT Imaging Following CAR-T Therapy","volume":"23","author":"Lutfi","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Brown, B.D., Tambaro, F.P., Kohorst, M., Chi, L., Mahadeo, K.M., Tewari, P., Petropoulos, D., Slopis, J.M., Sadighi, Z., and Khazal, S. (2021). Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.634445"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wei, Z., Xu, J., Zhao, C., Zhang, M., Xu, N., Kang, L., Lou, X., Yu, L., and Feng, W. (2023). Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1273507"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Long, C., Liu, X., Fang, H., Qi, H., Ma, C., Wang, H., and Li, Z. (2026). Systematic review and meta-analysis of PET-based prognostic metrics in CAR-T treatment of DLBCL. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1679181"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mulgaonkar, A., Udayakumar, D., Yang, Y., Harris, S., \u00d6z, O.K., Geethakumari, P.R., and Sun, X. (2023). Current and potential roles of immuno-PET\/-SPECT in CAR T-cell therapy. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1199146"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/4\/52\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:47:07Z","timestamp":1785142027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/4\/52"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["hematolrep18040052"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18040052","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}